Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 – 2 (canceled)

3. (previously presented) The method of claim 27 wherein the oil is selected from the group consisting of monogylcerides, diglycerides, triglycerides, and mixtures thereof.

4. (previously presented) The method of claim 27 wherein the oil is a plant oil.

5. (previously presented) The method of claim 4 wherein the plant oil is selected from the group consisting of soybean oil, cotton seed oil, safflower oil, corn oil, coconut oil, sesame oil, peanut oil, olive oil, and mixtures thereof.

6. (previously presented) The method of claim 27 wherein the oil is selected from the group consisting of soybean oil, fish oil, animal oil, mineral oil, and chemically-synthesized oil.

7. (canceled)

8. (previously presented) The method of claim 27 wherein the emulsifier is a phospholipid.

9 – 11 (canceled)

12. (previously presented) The method of claim 8 wherein the phospholipid is selected from the group comprising of egg yolk phospholipids, hydrogenated egg yolk phosphor lipids, soybean phospholipids, hydrogenated soybean phospholipids, and mixtures thereof.

13 – 15 (canceled)

16. (previously presented) The method of claim 27 wherein the emulsifier is a lecithin.

17. (canceled)

18. (previously presented) The method of claim 27 wherein the tonicity modifier is selected from the group consisting of glycerin, sorbital, polyoxyethylated hydrocarbons, and C_6-C_{20} saturated or unsaturated aliphatic acids.

19 – 20 (canceled)

21. (previously presented) The method of claim 27 wherein the tonicity modifier comprises glycerin.

22 – 24 (canceled)

25. (previously presented) The method of claim 27 wherein the emulsion comprises particles in the range of about 0.25 microns to about 0.75 microns in diameter.

26. (canceled)

27. (currently amended) A method for treating cardiotoxicity caused by a lipophilic or amphiphilic anesthetic agent, which comprises infusing a lipid emulsion composition

intravenously whereby the anesthetic agent permeates the lipid emulsion composition and is withdrawn from the bloodstream, said lipid emulsion comprising an oil, an emulsifier, a tonicity modifier, and water, wherein the oil is present in an amount in the range of about 10 to about 30 percent by weight, the water is present in an amount in the range of about 70 to about 90 percent by weight, and the emulsifier is present in an amount in the range of about 1 percent to about 5 percent by weight, wherein said anesthetic agent is selected from the group consisting of bupivacaine, lidocaine, tetracaine, and etidocaine.

28. (currently amended) The method of claim 27 wherein the lipid emulsion composition comprises about 20 weight percent ~~soybean~~ oil, where the oil is soybean oil, about 2 weight percent ~~glycerin~~ tonicity modifier, where the tonicity modifier is glycerin, and about 1 weight percent ~~egg yolk phospholipids~~ emulsifier, where the emulsifier is egg yolk phospholipids, and about 80 weight percent water.

29. (previously presented) The method of claim 27 wherein the lipid emulsion composition is intravenously infused at an initial rate in the range of about 7.5 milliliters per kilogram per minute for a time period of about 30 seconds followed by a steady-state rate in the range of about 3 milliliters per kilogram per minute for a time period of about 2 minutes.

30 – 39 (canceled)